Home / Specialties / Nephrology / DiaPep277m ® Preserves Beta-Cells in Newly Diagnosed Type 1 Diabetes

DiaPep277m ® Preserves Beta-Cells in Newly Diagnosed Type 1 Diabetes

Dec 5, 2006

Treatment of new-onset type 1 diabetes with peptide is safe and associated with preserved beta-cell function. Treatment with DiaPep277, a peptide, has been shown to preserve beta-cell function in a trial with newly diagnosed human patients with type 1 diabetes treated over a 10-month period.

This article extends the clinical trial observations to a total of 20 months of treatment to determine the safety and the effects of repeated doses of DiaPep277 on endogenous insulin secretion, metabolic control, and exogenous insulin requirements.

Thirty-five male patients (aged 16-58) with a basal C-peptide greater than 0.1 nmol/L were assigned to periodic treatment with DiaPep277 (1 mg) or placebo for a 12-month treatment and 18-month observation protocol, later extended to an additional year of treatment. Stimulated C-peptide, HbA(1c), and an exogenous insulin dose were the clinical endpoints.

At 18 months, stimulated C-peptide concentrations had fallen in the placebo group (p = 0.0005) but were maintained in the DiaPep277 group. The need for exogenous insulin was higher in the placebo group than in the DiaPep277 group. Mean HbA(1c) concentrations were similar in both groups. After extension of the study, patients continuing treatment with DiaPep277 and those switched from placebo to DiaPep277 manifested a trend towards a greater preservation of beta-cell function compared to patients maintained on or switched to placebo. The safety profile of DiaPep277 was similar between the treatment and placebo groups, and no drug-related adverse events occurred.

From the results it was concluded that periodic treatment of subjects with DiaPep277 over 2 years was safe and associated preservation of endogenous insulin secretion up to 18 months was observed.

Diabetes Metab Res Rev. 2006 Nov 24; [Epub ahead of print]


ACE Inhibitors Reduce Kidney Disease Risk in Diabetics with High Blood Pressure: In diabetic patients with hypertension, ACE inhibitors reduce the risk of developing diabetes-related kidney disease, independent of their effect in lowering blood pressure, reports a study in the December Journal of the American Society of Nephrology. Read and print the full news article at: http://www.diabetesincontrol.com/modules.php?name=News&file=article&sid=4379




Breaking News from the American Diabetes Association 66th Scientific Sessions
Did you miss the ADA Scientific Sessions in Washington, DC? Get up to speed on the latest research and updates to current knowledge on diabetes and dyslipidemia-FREE CME Activities from the ADA Scientific Sessions are now available! Click here to access the interactive CME newsletter summary of several presentations relevant to clinical practice and the CME case-based slide and audio presentations on the real-world management of patients with diabetes and dyslipidemia recorded at the ADA meeting. Don’t miss this opportunity to learn the latest clinical updates from one of the year’s most critical diabetes events!